Patents by Inventor Per-Ola Johansson

Per-Ola Johansson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HCV NS-3 serine protease inhibitors
    Patent number: 10172846
    Abstract: Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: January 8, 2019
    Assignee: Medivir AB
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
  • HCV NS-3 SERINE PROTEASE INHIBITORS
    Publication number: 20170196849
    Abstract: Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Application
    Filed: March 27, 2017
    Publication date: July 13, 2017
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
  • HCV NS-3 SERINE PROTEASE INHIBITORS
    Publication number: 20100166706
    Abstract: Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Application
    Filed: December 21, 2009
    Publication date: July 1, 2010
    Applicant: Medivir AB
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
  • HCV NS-3 serine protease inhibitors
    Patent number: 7671032
    Abstract: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: March 2, 2010
    Assignee: Medivir AB
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
  • HCV NS-3 Serine Protease Inhibitors
    Publication number: 20100003216
    Abstract: Compounds of the formula where the variables are as defined in the specification inhibit the NS3 protease of flavivirus sych as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Application
    Filed: September 11, 2009
    Publication date: January 7, 2010
    Applicant: Medivir AB
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Susana Ayesa, Bjorn Classon, Laszlo Rakos, Bertil Samuelsson
  • HCV NS-3 serine protease inhibitors
    Patent number: 7608590
    Abstract: Compounds of the formula where the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: October 27, 2009
    Assignee: Medivir AB
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Susana Ayesa, Bjorn Classon, Laszlo Rakos, Bertil Samuelsson
  • Hcv Ns-3 Serine Protease Inhibitors
    Publication number: 20070203072
    Abstract: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Application
    Filed: January 28, 2005
    Publication date: August 30, 2007
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
  • Hcv ns-3 serine protease inhibitors
    Publication number: 20070161574
    Abstract: Compounds of the formula where the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    Type: Application
    Filed: January 28, 2005
    Publication date: July 12, 2007
    Inventors: Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Susana Ayesa, Bjorn Classon, Laszlo Rakos, Bertil Samuelsson